BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23139258)

  • 1. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms.
    Caponi S; Funel N; Frampton AE; Mosca F; Santarpia L; Van der Velde AG; Jiao LR; De Lio N; Falcone A; Kazemier G; Meijer GA; Verheul HM; Vasile E; Peters GJ; Boggi U; Giovannetti E
    Ann Oncol; 2013 Mar; 24(3):734-41. PubMed ID: 23139258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas.
    Permuth-Wey J; Chen YA; Fisher K; McCarthy S; Qu X; Lloyd MC; Kasprzak A; Fournier M; Williams VL; Ghia KM; Yoder SJ; Hall L; Georgeades C; Olaoye F; Husain K; Springett GM; Chen DT; Yeatman T; Centeno BA; Klapman J; Coppola D; Malafa M
    PLoS One; 2015; 10(1):e0116869. PubMed ID: 25607660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
    Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
    Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of protein expression and clinical features.
    Nishikawa N; Kimura Y; Okita K; Zembutsu H; Furuhata T; Katsuramaki T; Kimura S; Asanuma H; Hirata K
    J Hepatobiliary Pancreat Surg; 2006; 13(4):327-35. PubMed ID: 16858545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas.
    Oda Y; Aishima S; Morimatsu K; Hayashi A; Shindo K; Fujino M; Mizuuchi Y; Hattori M; Tanaka M; Oda Y
    Hum Pathol; 2013 Aug; 44(8):1487-98. PubMed ID: 23465281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
    Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
    Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas.
    Iacobuzio-Donahue CA; Klimstra DS; Adsay NV; Wilentz RE; Argani P; Sohn TA; Yeo CJ; Cameron JL; Kern SE; Hruban RH
    Am J Pathol; 2000 Sep; 157(3):755-61. PubMed ID: 10980115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pdcd4 expression in intraductal papillary mucinous neoplasm of the pancreas: its association with tumor progression and proliferation.
    Hayashi A; Aishima S; Miyasaka Y; Nakata K; Morimatsu K; Oda Y; Nagai E; Oda Y; Tanaka M; Tsuneyoshi M
    Hum Pathol; 2010 Nov; 41(11):1507-15. PubMed ID: 20656320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of histological subtype in intraductal papillary mucinous neoplasm of the pancreas: A retrospective analysis of outcome from one single center.
    Rong Y; Wang D; Xu C; Ji Y; Jin D; Wu W; Xu X; Kuang T; Lou W
    Medicine (Baltimore); 2017 Apr; 96(15):e6599. PubMed ID: 28403101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44v6 expression in intraductal papillary mucinous neoplasms of the pancreas.
    Miyasaka Y; Nagai E; Ohuchida K; Nakata K; Hayashi A; Mizumoto K; Tsuneyoshi M; Tanaka M
    Pancreas; 2010 Jan; 39(1):31-5. PubMed ID: 19952968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct patterns of peritumoral histological findings in subtypes of intraductal papillary mucinous neoplasms of the pancreas.
    Saito M; Imada H; Suzuki T; Sata N; Yasuda Y; Maetani I; Fukushima N
    Ann Diagn Pathol; 2015 Oct; 19(5):347-52. PubMed ID: 26265194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms.
    Chang X; Yu C; Li J; Yu S; Chen J
    Int J Med Sci; 2017; 14(5):412-418. PubMed ID: 28539816
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry.
    Worni M; Akushevich I; Gloor B; Scarborough J; Chino JP; Jacobs DO; Hahn SM; Clary BM; Pietrobon R; Shah A
    Ann Surg Oncol; 2012 Apr; 19(4):1316-23. PubMed ID: 22002799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes.
    Lahat G; Lubezky N; Loewenstein S; Nizri E; Gan S; Pasmanik-Chor M; Hayman L; Barazowsky E; Ben-Haim M; Klausner JM
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S750-7. PubMed ID: 25069861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC1 and HER2 might be associated with invasive phenotype of intraductal papillary mucinous neoplasm.
    Ohira G; Kimura K; Yamada N; Amano R; Nakata B; Doi Y; Murata A; Yashiro M; Tanaka S; Ohsawa M; Wakasa K; Hirakawa K
    Hepatogastroenterology; 2013; 60(125):1067-72. PubMed ID: 23635475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of pancreatic margin status and lymph node metastases on recurrence after resection for invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis.
    Leng KM; Wang ZD; Zhao JB; Cui YF; Zhong XY
    Dig Surg; 2012; 29(3):213-25. PubMed ID: 22677789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm.
    Morimatsu K; Aishima S; Yamamoto H; Hayashi A; Nakata K; Oda Y; Shindo K; Fujino M; Tanaka M; Oda Y
    Hum Pathol; 2013 Sep; 44(9):1714-21. PubMed ID: 23597774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated expression level of microRNA-196a is predictive of intestinal-type intraductal papillary mucinous neoplasm of the pancreas.
    Aso T; Ohtsuka T; Tamura K; Ideno N; Kono H; Nagayoshi Y; Ohuchida K; Ueda J; Takahata S; Shindo K; Aishima S; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2014 Apr; 43(3):361-6. PubMed ID: 24622064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.
    Jamieson NB; Morran DC; Morton JP; Ali A; Dickson EJ; Carter CR; Sansom OJ; Evans TR; McKay CJ; Oien KA
    Clin Cancer Res; 2012 Jan; 18(2):534-45. PubMed ID: 22114136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.